Related Experiment Video

Updated: Aug 6, 2026

A Protocol for Roux-en-Y Gastric Bypass in Rats using Linear Staplers
11:58

A Protocol for Roux-en-Y Gastric Bypass in Rats using Linear Staplers

Published on: August 21, 2021

Rationale, design, and methods for glycemic control in the Bypass Angioplasty Revascularization Investigation 2

Michelle F Magee1, William L Isley,

  • 1MedStar Diabetes Institute, MedStar Research Institute at Washington Hospital Center and Georgetown University Hospital, Washington, DC 20010, USA. michelle.f.magee@medstar.net

The American Journal of Cardiology
|July 4, 2006
PubMed

Insights

Reducing insulin resistance may be more effective than insulin-boosting drugs for improving cardiovascular outcomes in type 2 diabetes patients. The BARI 2D trial compares these strategies to reduce mortality and coronary artery disease risk.

Area of Science:

  • Cardiology
  • Endocrinology
  • Metabolic Diseases

Background:

  • Accelerated atherosclerosis is a major concern in type 2 diabetes mellitus.
  • Hyperglycemia and insulin resistance are key proatherogenic factors.
  • Previous trials using insulin-increasing agents showed limited cardiovascular benefits despite microvascular improvements.

Purpose of the Study:

  • To compare the efficacy of an insulin-sensitizing strategy versus an insulin-providing strategy in type 2 diabetes patients.
  • To determine which strategy is superior for reducing mortality and coronary artery disease (CAD) risk.
  • To test the glycemic control hypothesis within the BARI 2D trial.

Main Methods:

  • The Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial is a randomized controlled trial.
  • Patients with type 2 diabetes and coronary artery disease are assigned to either an insulin-sensitizing or insulin-providing glycemic control strategy.
  • Cardiovascular outcomes, mortality, and CAD risk are primary endpoints.

Main Results:

  • This article presents the rationale, design, and methods of the BARI 2D trial.
  • Specific results regarding cardiovascular outcomes are not detailed in this abstract.
  • The study aims to provide critical data on optimal glycemic management for cardiovascular health in diabetes.

Conclusions:

  • The BARI 2D trial will elucidate whether targeting insulin resistance directly is superior to increasing insulin levels for managing cardiovascular risk in type 2 diabetes.
  • Findings will inform therapeutic decisions for patients with diabetes and coronary artery disease.
  • This research addresses a significant gap in understanding diabetes management and cardiovascular outcomes.

More Related Videos

Duodenal-Jejunal Bypass Surgery in Diet-Induced Obese Diabetic Mice08:50

Duodenal-Jejunal Bypass Surgery in Diet-Induced Obese Diabetic Mice

Published on: October 18, 2024

Related Concept Videos

Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...